Date set for Merck/ALK's ragweed tablet adcom
This article was originally published in Scrip
Executive Summary
The US FDA's allergenic products advisory committee will discuss ALK's biologic license application (BLA) for the investigational ragweed sublingual allergy immunotherapy (AIT) tablet on 28 January 2014.